Acute renal failure after alpha interferon therapy for chronic hepatitis C in renal transplant patients;Insuffisance renale aigue chez des transplantes renaux traites par interferon alpha pour une hepatite chronique C

Nephrologie

Volumn 17, Issue 4, 1996, Pages 247-254

  Rostaing, L ^a   Modesto, A ^a   Baron, E ^a   Cisterne, J M ^a   Chabannier, M H ^a   Tkaczuk, J ^a   Durand, D ^a   Suc, J M ^a  

^a CHU RANGUEIL   (France)

Author keywords

acute renal failure; alpha interferon; hepatitis C; renal transplantation

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; CYCLOSPORIN A; METHYLPREDNISOLONE; RECOMBINANT ALPHA2B INTERFERON; STEROID; CREATININE; CYCLOSPORIN;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG WITHDRAWAL; EDEMA; FEMALE; HEPATITIS C; HISTOLOGY; HUMAN; HUMAN TISSUE; KIDNEY TRANSPLANTATION; MALE; SUBCUTANEOUS DRUG ADMINISTRATION; AGED; BLOOD; MIDDLE AGED;

ADULT; AGED; CREATININE; CYCLOSPORINE; FEMALE; HEPATITIS C; HUMANS; INTERFERON-ALPHA; KIDNEY FAILURE, ACUTE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 0029693654     PISSN: 02504960     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992; 327: 1899-2005.
2. Roth D, Zucker K, Cirocco C, et al. The impact of hepatitis C virus infection on renal allograft recipients. Kidney Int 1994; 45: 238-44.
3. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alpha. N Engl J Med 1989; 321: 1501-5.
4. Saracco G, Rosina F, Abate ML, et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of Interferon-α 2b. Hepatology 1993; 18: 1300-5.
5. Selby P, Kohn J, Raymond J, Judson I, McElwain T. Nephrotic syndrome during treatment with interferon. Br Med J 1985; 290: 1180.
6. Traynor A, Kuzel T, Samuelson E, Kanwar Y, Minimal-change glomerulopathy and glomerular visceral epithelial hyperplasia associated with alpha-interferon therapy for cutaneous-T-cell lymphoma. Nephron 1994; 67: 94-100.
7. Kimmel PL, Abraham AA, Phillips TM. Membrano-proliferative glomerulonephritis in a patient treated with interferon-α for human immunodeficiency virus infection. Am J Kidney Dis 1994; 24: 858-63.
8. Herrman J, Gabriel F. Membrano-proliferative glomerulonephritis in a patient with hairy-cell leukemia treated with alpha-II interferon. N Engl J Med 1987; 316: 112-3.
9. Cardineau E, Reman O, Hurault de Ligny B, Ryckelynck JP. Glomerulonéphrite membrano-proliferative et interféron (Abst). Société Française de Néphrologie, Dijon, octobre 1994.
10. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JV. Clinical toxicity of interferons in cancer patients: A review. J Clin Oncol 1986; 4: 234-43.
11. Nair S, Johnston JO, Ernstoff MS, et al. Interferon-induced reversible acute renal failure with nephrotic syndrome. Urology 1992; 34: 169-72.
12. Fahal IH, Murry N, Chu P, Bell JM. Acute renal failure during interferon treatment. Br Med J 1993; 306: 973.
13. Noël C, Vrtovsnik F, Facon T, et al. Acute and definitive renal failure in progressive multiple myeloma treated with recombinant interferon alpha-2a: Report on two patients. Am J Hematol 1993; 41: 298-9.
14. Harvey M, Rosenfeld D, Davies D, Hall BM. Recombinant interferon alpha and hemolytic uremic syndrome: Cause or coincidence? Am J Hematol 1994; 46: 152-3.
15. Schlaifer D, Dumazer P, Spenatto N, et al. Hemolytic-uremic syndrome in a patient with chronic myelogenous leukemia treated with interferon alpha. Am J Hematol 1994; 47: 254-5.
16. Jadoul M, Piessevaux H, Ferrant A, Cosyns JP, van Ypersele deStrihou C. Renal thrombotic microangiopathy in patients with chronic myelogenous leukaemia treated with interferon 2b. Nephrol Dial Transplant 1995; 10: 111-3.
17. Averbuch SD, Austin HA, Sherwin SA, et al. Acute intertitial nephritis with the nephrotic syndrome following recombinant leucocyte A interferon therapy for mycosis fungoides. N Engl J Med 1984; 310: 32-5.
18. Durand JM, Retornaz F, Cretel E, Kaplanski G, Soubeyrand J. Glomerulonéphrite extracapillaire au cours d'un traitement par interféron alpha. Rev Med Interne 1993; 14: 1138.
19. Kramer P, Ten Kate FWJ, Bijnen AB, et al. Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients. Lancet 1984; I: 989-90.
20. Weimar W, Kramer P, Bijnen AB, et al. The incidence of cytomegalo - and herpes simplex virus infections in renal allograft recipients treated with high dose recombinant leucocyte interferon: A controlled study. Scand J Urol Nephrol 1985; 92 (Suppl.): 37-9.
21. Kovarik J, Mayer G, Pohanka E, et al. Adverse effect of low-dose prophylactic human recombinant leucocyte interferon-alpha treatment in renal transplant recipients. Transplantation 1988; 45: 402-5.
22. Magnone M, Holley JM, Shapiro R, et al. Interferon-α-induced acute renal allograft rejection. Transplantation 1995; 59: 1068-70.
23. Morel-Maroger L, Slopper JC, Vinter J, et al. An ultrastructural study of the developement of nephritis in mice treated with interferon in the neonatal period. Lab Invest 1978; 39: 513-22.
24. Moss J, Shore I, Woodrow D, Gresser I. Interferon-induced glomerular basement membrane and endothelial cell lesions in mice. Am J Pathol 1988; 133: 557-63.
25. Gresser I. Can interferon induce disease? Interferon 4. Edited by Gresser I. New York Academic Press, 1982; 95-127.
26. Hirsch MS, Schooley RT, Cosimi AB, et al. Effects of interferon alpha on cytomegalovirus reactivation syndromes in renal transplant recipients. N Engl. J Med 1983; 308: 1489-93.
27. Lui SF, Ali AA, Grundy JE, et al. Double-blind, placebo-controlled trial of human lymphoblastoid interferon prophylaxis of cytomegalovirus infection in renal transplant recipients. Nephrol Dial Transplant 1992; 7: 1230-7.
28. Rhodes J, Jones DH, Bleehen NM. Increased expression of human monocyte HLA-DR antigens and Fcγ receptors in response to human interferon in vivo. Clin Exp Immunol 1983; 53: 739-43.
29. Giacomini P, Fraioli R, Calabro AM, et al. Class I major histocompatibility complex enhancement by recombinant leucocyte interferon in the peripheral blood mononuclear cells and plasma of melanoma patients. Cancer Res 1991; 51: 652-6.
30. Ault BH, Bruder-Stapleton F, Gaber L, et al. Acute renal failure during therapy with recombinant human gamma interferon. N Engl J Med 1988; 319: 1397-400.
31. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologie diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411-22.
32. Thervet E, Pol S, Gagnadoux MF, et al. Low-dose recombinant leukocyte interferon-α treatment of hepatitis C viral infection transplant recipients. Transplantation 1994; 58: 625-8.
33. Harihara Y, Kurooka Y, Yanagisawa T, et al. Interferon therapy in renal allograft recipients with chrome hepatitis C. Transplant Proc, 1994; 26: 2075.
34. Quiroga JA, Martin J, Bosch O, Carreno V. Immunological studies in patients with chronic hepatitis C. Factors affecting response to interferon alpha. Hepatology 1991; 14: 216A.
35. Tilg H, Vogel W, Dinarello CA. Interferon-α induces circulating tumor necrosis factor receptor p 55 in humans. Blood 1985; 85: 433-5.